CVR: 30919246
Secondary names: NOVOZYMES BIOLOGICALS HOLDING A/S, Novozymes BioAg A/S
Novonesis Plant Biosolutions A/S exhibits strong financial health, marked by a significant profit of 520,581,561 DKK in 2025, up from 403,926,577 DKK in 2024. Revenue has shown a steady increase, rising from 112,486,821 DKK in 2023 to 126,088,828 DKK in 2025, despite a notable dip in 2022. The company's equity position is robust at 853,779,346 DKK, indicating a solid foundation for future growth. However, the sharp decline in revenue in 2022 raises concerns about market volatility. Overall, Novonesis is well-positioned within its industry, benefiting from strong profitability and a healthy equity base.
AI-generated summary
Selskabets formål er drift af og investering i forskning, udvikling, produktion og handel med biologiske løsninger, herunder bioteknologiske produkter og processer samt at drive virksomhed, der efter bestyrelsens nærmere bestemmelse står i forbindelse hermed. Selskabet tilstræber at drive sin virksomhed på bæredygtig og ansvarlig vis, herunder i økonomisk, miljømæssig og social henseende.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 126.1 mio. | 520.6 mio. | 1.2 mia. | 853.8 mio. | - | |
Compared to 221 companies in Leasing af intellektuelle ejendomsrettigheder og lignende produkter, dog ikke ophavsretsbeskyttede værker
Comparison is based on industry median values
Companies in the same industry and area
CVR 45944611
CVR 42794295
CVR 35207147
CVR 27985653
CVR 45644855
companydata.dk